BiotechTube

Quetiapine

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Depression

Conditions

Depression, Bipolar Disorder

Trial Timeline

Jan 15, 2018 → Mar 19, 2020

NCT ID
NCT03403790

About Quetiapine

Quetiapine is a pre-clinical stage product being developed by Astellas Pharma for Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT03403790. Target conditions include Depression, Bipolar Disorder.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT03403790Pre-clinicalCompleted

Competing Products

20 competing products in Depression

See all competitors
ProductCompanyStageHype Score
Olanzapine and Fluoxetine combination (OFC) + FluoxetineEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
duloxetine + escitalopram + placeboEli LillyPhase 3
77
duloxetineEli LillyApproved
85
Duloxetine HydrochlorideEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
DuloxetineEli LillyApproved
85
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)Eli LillyApproved
85
Duloxetine + PlaceboEli LillyPhase 3
77
DuloxetineEli LillyApproved
85
duloxetine + fluoxetine + citalopram + paroxetine + sertralineEli LillyApproved
85
Olanzapine + PlaceboEli LillyPhase 3
77
Olanzapine + Fluoxetine + PlaceboEli LillyPhase 3
77
duloxetine + duloxetineEli LillyPre-clinical
23
olanzapine + ziprasidoneEli LillyApproved
85
Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved
85
Drug treatment with CymbaltaEli LillyApproved
85
DuloxetineEli LillyApproved
85
DuloxetineEli LillyApproved
85

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85